FMP
NASDAQ
2.02 USD
-0.05 (-2.48%)
Dr. Sean A. McCarthy DPHIL
Healthcare
Biotechnology
https://www.cytomx.com
NASDAQ
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical tri...
0001501989
US23284F1057
23284F105
151 Oyster Point Boulevard
650 515 3185
US
120
Oct 8, 2015
0001501989
NASDAQ
Biotechnology
Healthcare
23284F105
US23284F1057
US
2.02
1.01
854.04k
136.8M
-
1.04-2.855
-0.04
-
-
-
-
-202
-
https://www.cytomx.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.